To conclude, both the overexpression and activation of the serum/glucocorticoid regulated kinase 1 (SGK1)/Nuclear Factor (NF)-κB pathway are involved with the low sensitivity of multiple myeloma (MM) cells to bortezomib and ixazomib, and SGK1 or NF-κB inhibitors can be used to increase the cytotoxic effects of bortezomib and ixazomib. Here, NFKB1 is linked to plasma cell myeloma.